Business Wire

Spain’s CESGA Selects IQM and Telefónica to Deploy Advanced Quantum Computing Infrastructure

23.12.2025 10:53:00 EET | Business Wire | Press release

Share

IQM Quantum Computers, the global leader in deployed, on-premises computers, and Telefónica, a global telecommunications provider, have joined forces to sign a purchase agreement with the Galician Supercomputing Center (CESGA) to install two full-stack quantum computers in Spain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223742835/en/

Spain’s CESGA selects IQM and Telefónica to deploy advanced quantum computing infrastructure

Under the agreement, IQM will deliver and install a 54-qubit IQM Radiance, designed for integration into high-performance computing centres, together with a 5-qubit IQM Spark system dedicated to education. The systems are scheduled for delivery by June 2026.

The deployment will expand CESGA’s advanced computing capabilities and strengthen its role as a key national and European research infrastructure.

The systems will be used by the scientific community and made accessible to leading companies across multiple industrial and research sectors, enabling experimentation with hybrid workflows that combine quantum computing, artificial intelligence, and high-performance computing.

This will be the first installation of IQM quantum computers in Spain, positioning CESGA alongside leading European centres such as the Leibniz Supercomputing Centre (LRZ) and Jülich in Germany, CSC in Finland, and CINECA in Italy, which are integrating quantum systems into national HPC environments.

The systems will be complemented by a new supercomputer, the Finisterrae IV, which will provide additional computing power to meet needs in artificial intelligence, among others, and a data storage system that will make it possible to permanently house large amounts of data and provide more advanced data services.

“Delivering production-grade quantum infrastructure into real HPC environments is central to IQM’s mission,” said Sylwia Barthel de Weydenthal, Chief Commercial Officer of IQM Quantum Computers. “By deploying our systems at CESGA, we are supporting the development of a practical quantum ecosystem in Spain and enabling researchers and industry users to begin meaningful experimentation with hybrid quantum-classical computing.”

“Quantum computing will become an important pillar of future digital infrastructure,” said Sergio Sánchez, CTIO Telefónica España. “Through this collaboration with IQM and CESGA, Telefónica is helping bring advanced computing capabilities closer to researchers and enterprises, while supporting Spain’s position in next-generation technologies.”

About IQM Quantum Computers

IQM Quantum Computers is a global leader in the deployment of superconducting quantum computing systems, delivering full-stack, on-premises quantum infrastructure designed to integrate into advanced computing environments. IQM works with high-performance computing centers, research institutions, universities, and enterprises, providing access to both quantum hardware and software. Headquartered in Finland, IQM employs more than 300 people and operates globally, with teams in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States. For more information, visit www.meetiqm.com.

About Telefónica:

Telefónica is one of the world’s leading telecommunications service providers. The company offers fixed and mobile connectivity as well as a wide range of digital services for residential and business customers. With over 350 million customers, Telefónica operates in Europe and Latin America. Telefónica is listed on the Spanish stock market, New York and Lima.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251223742835/en/

Contacts

Media contact:
press@meetiqm.com
+358 50 479 0845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meetiqm.com
%2F&esheet=54383096&newsitemid=20251223742835&lan=en-US&anchor=www.meetiqm.com&i
ndex=2&md5=f173a1626ad58075154e417e9f128266

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye